Alumis stands to bulk up its financial position as well as its portfolio of drugs to treat immune-mediated diseases through its merger with Acelyrin. But while analysts saw the deal as a positive from a financial standpoint, management comments about Acelyrin’s lead product candidate, lonigutamab, created uncertainty about the drug’s future as the company said it would look to analyze the program’s value instead of immediately going ahead with a Phase III study.
Alumis To Merge With Acelyrin, But Pause Lonigutamab Program
Alumis said it will pause the planned Phase III program for Acelyrin’s lead drug and assess the value of the candidate, which produced underwhelming Phase II results in January.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.